Will Pharma Reach a Negative Return on its R&D Investments?
It isn’t news that pharma’s business model is in trouble, but a new report from Evaluate and number crunching from Endpoints show the size of the problem. Pharma depends on innovation, which is why it turns to biotech as the powerhouse of novel technologies. About 65% of recently drugs come from small life sciences companies … Continue reading Will Pharma Reach a Negative Return on its R&D Investments?
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed